{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:11:28Z","timestamp":1787969488880,"version":"build-2784847793"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262265\u201302"],"award-info":[{"award-number":["R01CA262265\u201302"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006954","name":"Tufts Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.blre.2024.101170","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T21:41:47Z","timestamp":1705527707000},"page":"101170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Harnessing multi-source data for individualized care in Hodgkin Lymphoma"],"prefix":"10.1016","volume":"65","author":[{"given":"Susan K.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenica N.","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton D.","family":"Scharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung Ryu","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bjh.15623","article-title":"Therapeutic recommendations for early stage Hodgkin lymphomas","volume":"184","author":"Depaus","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bjh.15736","article-title":"Important new developments in Hodgkin lymphoma","volume":"184","author":"Evens","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2024.101170_bb0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/bjh.16587","article-title":"How I treat advanced Hodgkin lymphoma - a global view","volume":"190","author":"Hokland","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15622","article-title":"Current treatment paradigms for advanced stage Hodgkin lymphoma","volume":"184","author":"Longley","year":"2019","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.blre.2024.101170_bb0030","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjh.13372","article-title":"Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents","volume":"169","author":"Giulino-Roth","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2024.101170_bb0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2024.101170_bb0045","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2024.101170_bb0050","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/cncr.25053","article-title":"A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects","volume":"116","author":"Hodgson","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.blre.2024.101170_bb0055","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.23081","article-title":"Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.blre.2024.101170_bb0060","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2024.101170_bb0065","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2024.101170_bb0070","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second Cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0075","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood Cancer survivor study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"issue":"10112","key":"10.1016\/j.blre.2024.101170_bb0080","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0140-6736(17)31610-0","article-title":"The cumulative burden of surviving childhood cancer: an initial report from the St Jude lifetime cohort study (SJLIFE)","volume":"390","author":"Bhakta","year":"2017","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.blre.2024.101170_bb0085","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0090","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0095","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0100","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients","volume":"113","author":"de Vries","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-016-0515-6","article-title":"Health-related quality of life in Hodgkin lymphoma: a systematic review","volume":"14","author":"Linendoll","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.blre.2024.101170_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw249","article-title":"Hodgkin lymphoma: current status and clinical trial recommendations","volume":"109","author":"Diefenbach","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.blre.2024.101170_bb0115","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2014-05-577627","article-title":"The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease","volume":"124","author":"Evens","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101170_bb0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/2040620715625615","article-title":"The evolving role of response-adapted PET imaging in Hodgkin lymphoma","volume":"7","author":"Coyle","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"10.1016\/j.blre.2024.101170_bb0125","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.blre.2024.101170_bb0130","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2024.101170_bb0135","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.blre.2024.101170_bb0140","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101170_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.blre.2024.101170_bb0150","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0155","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2024.101170_bb0170","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin study group HD7 to HD12 trials","volume":"35","author":"Brockelmann","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2024.101170_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-022-00674-w","article-title":"Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors","volume":"12","author":"Vassilakopoulos","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.18180","article-title":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - a study from the Danish lymphoma registry","volume":"198","author":"Andersen","year":"2022","journal-title":"Br J Haematol"},{"issue":"35","key":"10.1016\/j.blre.2024.101170_bb0185","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1200\/JCO.20.02668","article-title":"Continuum of Care for Hodgkin Lymphoma: impact of modern therapy on Postacute morbidity and mortality","volume":"38","author":"Evens","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2024.101170_bb0190","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cncr.34701","article-title":"Loss to follow-up of minorities, adolescents, and young adults on clinical trials: a report from the Children\u2019s oncology group","volume":"129","author":"Puthenpura","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2024.101170_bb0195","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/cncr.34702","article-title":"Vulnerable populations in childhood cancer research and clinical care","volume":"129","author":"Nathan","year":"2023","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.blre.2024.101170_bb0200","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.3138","article-title":"Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: an IMPACT cohort study","volume":"9","author":"Gupta","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.blre.2024.101170_bb0205","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2024.101170_bb0210","author":"HoLISTIC Consortium"},{"key":"10.1016\/j.blre.2024.101170_bb0215","series-title":"The Hodgkin Lymphoma International Study for Individual Care (HOLISTIC): A Multi-National Collaborative to Enhance Decision Making for Pediatric and Adult Hodgkin Lymphoma (HL). Poster presented at European Hematology Association (EHA)","author":"Evens","year":"2020"},{"issue":"21","key":"10.1016\/j.blre.2024.101170_bb0220","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada clinical trials group and the eastern cooperative oncology group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0225","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101170_bb0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","volume":"81","author":"Ferme","year":"2017","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.blre.2024.101170_bb0235","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2024.101170_bb0240","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2024.101170_bb0245","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.blre.2024.101170_bb0250","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin\u2019s lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0255","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo studio Dei Linfomi trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.blre.2024.101170_bb0260","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin\u2019s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0265","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the eastern cooperative oncology group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0270","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2024.101170_bb0275","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101170_bb0280","author":"National Cancer Institute"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0285","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction","volume":"98","author":"Hahn","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.blre.2024.101170_bb0290","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.24386","article-title":"The association between socioeconomic status and survival among children with Hodgkin and non-Hodgkin lymphomas in a universal health care system","volume":"60","author":"Darmawikarta","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0295","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0300","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101170_bb0305","author":"Bhakta","year":"2019"},{"issue":"9","key":"10.1016\/j.blre.2024.101170_bb0310","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude lifetime cohort study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.blre.2024.101170_bb0315","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.blre.2024.101170_bb0320","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2024.101170_bb0325","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2024.101170_bb0330","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005927","article-title":"Effect of variable selection strategy on the performance of prognostic models when using multiple imputation","volume":"12","author":"Austin","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7590","key":"10.1016\/j.blre.2024.101170_bb0335","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.38977.682025.2C","article-title":"Missing data","volume":"334","author":"Altman","year":"2007","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.blre.2024.101170_bb0340","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"issue":"16","key":"10.1016\/j.blre.2024.101170_bb0345","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/sim.1844","article-title":"Validation and updating of predictive logistic regression models: a study on sample size and shrinkage","volume":"23","author":"Steyerberg","year":"2004","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0350","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0355","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(03)00047-7","article-title":"Internal and external validation of predictive models: a simulation study of bias and precision in small samples","volume":"56","author":"Steyerberg","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.blre.2024.101170_bb0360","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-023-02779-w","article-title":"There is no such thing as a validated prediction model","volume":"21","author":"Van Calster","year":"2023","journal-title":"BMC Med"},{"issue":"23","key":"10.1016\/j.blre.2024.101170_bb0365","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/sim.6997","article-title":"A new concordance measure for risk prediction models in external validation settings","volume":"35","author":"van Klaveren","year":"2016","journal-title":"Stat Med"},{"issue":"29","key":"10.1016\/j.blre.2024.101170_bb0370","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0375","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"issue":"11","key":"10.1016\/j.blre.2024.101170_bb0380","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced-stage Hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the HoLISTIC consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2024.101170_bb0385","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.blre.2024.101170_bb0390","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2024.101170_bb0395","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/1740774518789098","article-title":"Application of multi-state models in cancer clinical trials","volume":"15","author":"Le-Rademacher","year":"2018","journal-title":"Clin Trials"},{"issue":"3","key":"10.1016\/j.blre.2024.101170_bb0400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40471-022-00291-y","article-title":"The utility of multistate models: a flexible framework for time-to-event data","volume":"9","author":"Le-Rademacher","year":"2022","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"10.1016\/j.blre.2024.101170_bb0405","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-014-2246-2","article-title":"A multi-state model approach for prediction in chronic myeloid leukaemia","volume":"94","author":"Lauseker","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2024.101170_bb0410","series-title":"The theory of stochastic processes","author":"Cox","year":"1965"},{"issue":"8","key":"10.1016\/j.blre.2024.101170_bb0415","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/sim.8882","article-title":"Power and sample size for multistate model analysis of longitudinal discrete outcomes in disease prevention trials","volume":"40","author":"Smith","year":"2021","journal-title":"Stat Med"},{"issue":"15_suppl","key":"10.1016\/j.blre.2024.101170_bb0420","doi-asserted-by":"crossref","first-page":"12068","DOI":"10.1200\/JCO.2020.38.15_suppl.12068","article-title":"Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): a simulation study from the St. Jude lifetime (SJLIFE) cohort and HL international study for individual care (HoLISTIC)","volume":"38","author":"Parsons","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:26:05Z","timestamp":1713367565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":84,"alternative-id":["S0268960X24000031"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101170","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing multi-source data for individualized care in Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101170"}}